Basilea Pharmaceutica AG (0QNA.L)

41,55 -0,40 (-0,95%) In data: 10:15AM BST. Mercato aperto.

Basilea Pharmaceutica AG

Hegenheimermattweg 167b
Allschwil 4123
Switzerland
41 61 606 11 11
https://www.basilea.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 147

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. David Veitch	Chief Executive Officer	1,13M	N/D	1965
Mr. Adesh Kaul	Chief Financial Officer	N/D	N/D	1974
Dr. Gerrit Hauck Ph.D.	Chief Technology Officer	N/D	N/D	1964
Dr. Laurenz Kellenberger Ph.D.	Chief Scientific Officer	N/D	N/D	1967
Dr. Marc Engelhardt M.D.	Chief Medical Officer	N/D	N/D	1964
Dr. Peer Nils Schroder	Head of Corporate Communications & Investor Relations	N/D	N/D	N/D
Mr. Damian Heller	General Counsel & Corporate Secretary	N/D	N/D	1966
Mr. Andreas Kumin	Head of Corporate Development	N/D	N/D	N/D
Ms. Ursula Eberhardt	Head of Global Human Resources	N/D	N/D	1962
Mr. Mark Jones	Head of Project Management & Preclinical Development	N/D	N/D	1968

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in CHF.

Descrizione

Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union. It also offers medicine drug for invasive fungal infections. In addition, the company provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as offers treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. Further, it offers Fosmanogepix, an antifungal drug for the treatment of Candidemia which in Phase II clinical trials. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.

Governance aziendale

L'ISS Governance QualityScore di Basilea Pharmaceutica AG al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.